In conclusion, our preclinical findings provide a rationale for combined targeting of mTOR and somatostatin signaling pathways as a promising approach for thyroid cancer therapy and provide further support for the ongoing exploration of this combination strategy in the clinic for the treatment of thyroid cancer and other neuroendocrine tumors. This evidence concerns the gene MTOR and thyroid gland carcinoma.